SCHEDULE 13G/A 0001193125-21-276241 0001224962 XXXXXXXX LIVE 6 Common Stock, $0.00001 par value 12/31/2025 0001661053 enVVeno Medical Corporation 29415J106 70 Doppler Irvine CA 92618 Rule 13d-1(c) Perceptive Advisors LLC b DE 0 2048515 0 2048515 2048515 N 9.99 IA Joseph Edelman b X1 0 2048515 0 2048515 2048515 N 9.99 IN Perceptive Life Sciences Master Fund, Ltd. b E9 0 2048515 0 2048515 2048515 N 9.99 enVVeno Medical Corporation 70 Doppler, Irvine, California 92618 The names of the persons filing this report (collectively, the "Reporting Persons") with respect to shares of Common Stock, par value $0.00001 per share (the "Common Stock") of enVVeno Medical Corporation (the "Issuer") are: (i) Perceptive Advisors LLC ("Perceptive Advisors") (ii) Joseph Edelman ("Mr. Edelman") (iii) Perceptive Life Sciences Master Fund, Ltd. (the "Master Fund") The address of the principal business office of each of the Reporting Persons is: 51 Astor Place, 10th Floor, New York, NY 10003 Perceptive Advisors is a Delaware limited liability company. Mr. Edelman is a United States citizen. The Master Fund is a Cayman Islands corporation. Y The information required by this item with respect to each Reporting Person is set forth in Rows 5 through 9 and 11 of the cover pages to this Schedule 13G. The ownership percentages are based on 20,216,176 outstanding shares of Common Stock as of October 28, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on October 30, 2025, and assume the exercise of Warrants held by the Reporting Persons for 289,480 shares of Common Stock (the " Warrants"). Neither Perceptive Advisors nor Mr. Edelman directly hold any shares of Common Stock or any Warrants. The Master Fund directly holds 1,759,035 shares of Common Stock and 861,192 Warrants immediately exercisable for shares of Common Stock at an exercise price of $8.334 per share, subject to the Beneficial Ownership Limitation (as defined below). The terms of the Warrants provide that the Warrants may not be exercised if, after such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) if the Securities Exchange Act of 1934, as amended, more than 9.99% of the shares of Common Stock then issued and outstanding (the "Beneficial Ownership Limitation"). As of the date hereof, the Beneficial Ownership Limitation permits the Reporting Persons to exercise Warrants for an aggregate of not more than 289,480 shares of Common Stock. In providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that the aggregate remaining Warrants held by the Reporting Persons are not exercisable due to the Beneficial Ownership Limitation. Perceptive Advisors serves as the investment manager to the Master Fund. Mr. Edelman is the managing member of Perceptive Advisors. Perceptive Advisors: 9.99% Mr. Edelman: 9.99% Master Fund: 9.99% Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 2,048,515 Mr. Edelman: 2,048,515 Master Fund: 2,048,515 Perceptive Advisors: 0 Mr. Edelman: 0 Master Fund: 0 Perceptive Advisors: 2,048,515 Mr. Edelman: 2,048,515 Master Fund: 2,048,515 Y Y Y Y Y N By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. Perceptive Advisors LLC /s/ Joseph Edelman 02/17/2026 Joseph Edelman /s/ Joseph Edelman 02/17/2026 Perceptive Life Sciences Master Fund, Ltd. /s/ Joseph Edelman 02/17/2026